Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Risperidone · Risperdal, Rykindo Extended-Release Microspheres

Small molecule · Antagonist of dopamine D2 receptor (DRD2) and serotonin 5-HT2 receptor (HTR2A) · developed by Janssen Pharms

Approved FDA, Dec 1993
1 Registered trials

What is Risperidone?

Risperidone is an atypical antipsychotic that acts as an antagonist at dopamine D2 and serotonin 5-HT2 receptors, with additional receptor antagonism that may account for other effects. It is used in the treatment of schizophrenia, and an extended-release subcutaneous injectable formulation is studied in schizophrenia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Risperdal, Rykindo Extended-Release Microspheres, Uzedy, LY-03004, NSC-759895, PERSERIS
Drug type
Small molecule
Targets
dopamine D2 receptor (DRD2), serotonin 5-HT2 receptor (HTR2A)
Mechanism
Antagonist of dopamine D2 receptor (DRD2) and serotonin 5-HT2 receptor (HTR2A)
Therapy area
Psychiatry
Developer
Janssen Pharms
In trials of
INDV
FDA status
Approved as Risperdal, Rykindo Extended-Release Microspheres, Uzedy (December 29, 1993), NDA020272 · FDA label
UNII
L6UH7ZF8HC

✅ FDA-approved uses

From the indications section of the FDA label (version of May 26, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03978832 Phase 4 Schizophrenia Completed INDV

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Schizophrenia

Other drugs acting on DRD2 / HTR2A

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.